Correction: Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies

Código QR

Correction: Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies

Guardado en:

Detalles Bibliográficos
Formato:	article
Lenguaje:	EN
Publicado:	BMJ Publishing Group 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/2c3cf6c0e6c8463c9d2bb0fba7795f9c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types
por: Marco Donia, et al.
Publicado: (2021)

Systemic immune reaction in axillary lymph nodes adds to tumor-infiltrating lymphocytes in triple-negative breast cancer prognostication
por: Fangfang Liu, et al.
Publicado: (2021)

PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine
por: Mariaelena Pierobon, et al.
Publicado: (2021)

DNA methylation-based signature of CD8+ tumor-infiltrating lymphocytes enables evaluation of immune response and prognosis in colorectal cancer
por: Rish K Pai, et al.
Publicado: (2021)

Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy
por: Federica Cappuccini, et al.
Publicado: (2021)

Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy
por: James Harber, et al.
Publicado: (2021)

The Oncogenic Role and Immune Infiltration for CARM1 Identified by Pancancer Analysis
por: Kui Liu, et al.
Publicado: (2021)

Precision cancer therapy is impacted by oncogene-dependent epigenome remodeling
por: Feng Liu, et al.
Publicado: (2017)

Circulating tumor cells: quintessential precision oncology presenting challenges for biology
por: Rebecca J. Morris
Publicado: (2017)

Correction: Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma
Publicado: (2021)

Mitochondrial reactive oxygen species trigger metformin-dependent antitumor immunity via activation of Nrf2/mTORC1/p62 axis in tumor-infiltrating CD8T lymphocytes
por: Kazuhiro Kakimi, et al.
Publicado: (2021)

Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients
por: Yves Boucher, et al.
Publicado: (2021)

Correction: Immunologically programming the tumor microenvironment induces the pattern recognition receptor NLRC4-dependent antitumor immunity
Publicado: (2021)

Correction: IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy
Publicado: (2021)

Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology
por: Frank P. Lin, et al.
Publicado: (2021)

A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trial
por: Istvan Petak, et al.
Publicado: (2021)

Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity
por: Alberto Mantovani, et al.
Publicado: (2021)

Clinical implications of systemic and local immune responses in human angiosarcoma
por: Jason Yongsheng Chan, et al.
Publicado: (2021)

Correction: Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer
Publicado: (2021)

Correction: MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer
Publicado: (2021)

Multiplex imaging reveals the architecture of the tumor immune microenvironment
por: Junlei Zhang, et al.
Publicado: (2021)

Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study
por: Apostolia Maria Tsimberidou, et al.
Publicado: (2021)

Identification of an Immune-Related Biomarker Model Based on the CircRNA-Associated Regulatory Network for Esophageal Carcinoma
por: Zhaonian Hu, et al.
Publicado: (2021)

Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy
por: Sjoerd H van der Burg, et al.
Publicado: (2021)

Correction notice to “Combination therapy with dendritic cell vaccine and programmed death ligand 1 immune checkpoint inhibitor for hepatocellular carcinoma in an orthotopic mouse model”
por: Chiao-Fang Teng, et al.
Publicado: (2021)

Correction: In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis
Publicado: (2021)

Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival
por: Vladimir Lazar, et al.
Publicado: (2021)

Surgical Insights Are Essential to Integration of Immune Therapy in Resectable NSCLC
por: Jessica S. Donington, MD
Publicado: (2021)

Neoadjuvant immune checkpoint inhibitor plus chemotherapy in rare tracheal tumors
por: Ben‐Yuan Jiang, et al.
Publicado: (2021)

Spatiotemporal depletion of tumor-associated immune checkpoint PD-L1 with near-infrared photoimmunotherapy promotes antitumor immunity
por: Shunichi Taki, et al.
Publicado: (2021)

Precision oncology- the future of personalized cancer medicine?
por: Ann M. Bode, et al.
Publicado: (2017)

Precision medicine: the foundation of future cancer therapeutics
por: Seung Ho Shin, et al.
Publicado: (2017)

Artificial intelligence for the next generation of precision oncology
por: Pedro J. Ballester, et al.
Publicado: (2021)

Correction: Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids
Publicado: (2021)

Multiparametric MRI of early tumor response to immune checkpoint blockade in metastatic melanoma
por: Frank Riemer, et al.
Publicado: (2021)

Immunosuppressive metabolites in tumoral immune evasion: redundancies, clinical efforts, and pathways forward
por: David Munn, et al.
Publicado: (2021)

Distinct mutational profile and immune microenvironment in microsatellite-unstable and POLE-mutated tumors
por: Hee Sang Hwang, et al.
Publicado: (2021)

Epithelial cells mimic immune cells: a novel path toward tumor immunotherapy
por: Ruining Gong, et al.
Publicado: (2021)

Correction: Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition
Publicado: (2021)

Immune landscape in vulvar cancer-draining lymph nodes indicates distinct immune escape mechanisms in support of metastatic spread and growth
por: Gemma G Kenter, et al.
Publicado: (2021)